ArticleAging and disease2020
Geroscience in the Age of COVID-19.
Article in Aging and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Emerging uncertainty on the anti-aging potential of metformin.Ageing research reviews · 2025Review
- Gender difference in the association between volunteering and health-related quality of life among hearing-impaired older adults in China.BMC geriatrics · 2024Article
- Article
- Longevity Science and Women's Health and Wellbeing.Journal of population ageing · 2023Article
- The interplay of post-acute COVID-19 syndrome and aging: a biological, clinical and public health approach.Ageing research reviews · 2022Review
- A vicious cycle of health (in)equity: Migrant inclusion in light of COVID-19.Health policy and technology · 2022Article
- SARS-CoV-2 Morbidity in the CNS and the Aged Brain Specific Vulnerability.International journal of molecular sciences · 2022Review
- The Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China.Frontiers in aging neuroscience · 2022Article
- Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms.Cell research · 2021Article
- Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS.NPJ Regenerative medicine · 2021Article
- All Nations Must Prioritize the COVID-19 Vaccination Program for Elderly Adults Urgently.Aging and disease · 2021Article
- Review
- A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19.Aging and disease · 2020Article
- The geroscience agenda: Toxic stress, hormetic stress, and the rate of aging.Ageing research reviews · 2020Review
- COVID-19: A Challenge to Physiology of Aging.Frontiers in physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.